These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

292 related items for PubMed ID: 27283965

  • 1. CD44 SNPrs187115: A Novel Biomarker Signature that Predicts Survival in Resectable Pancreatic Ductal Adenocarcinoma.
    Stracquadanio G, Vrugt B, Flury R, Schraml P, Würl P, Müller TH, Knippschild U, Henne-Bruns D, Breitenstein S, Clavien PA, Graf R, Bond GL, Grochola LF.
    Clin Cancer Res; 2016 Dec 15; 22(24):6069-6077. PubMed ID: 27283965
    [Abstract] [Full Text] [Related]

  • 2. Identification and Validation of a Biomarker Signature in Patients With Resectable Pancreatic Cancer via Genome-Wide Screening for Functional Genetic Variants.
    Dimitrakopoulos C, Vrugt B, Flury R, Schraml P, Knippschild U, Wild P, Hoerstrup S, Henne-Bruns D, Wuerl P, Graf R, Breitenstein S, Bond G, Beerenwinkel N, Grochola LF.
    JAMA Surg; 2019 Jun 01; 154(6):e190484. PubMed ID: 30942874
    [Abstract] [Full Text] [Related]

  • 3. A Predictive Noninvasive Single-Nucleotide Variation-Based Biomarker Signature for Resectable Pancreatic Cancer: Protocol for a Prospective Validation Study.
    Seeger N, Gutknecht S, Zschokke I, Fleischmann I, Roth N, Metzger J, Weber M, Breitenstein S, Grochola LF.
    JMIR Res Protoc; 2024 May 13; 13():e54042. PubMed ID: 38635586
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. UNR/CDSE1 expression as prognosis biomarker in resectable pancreatic ductal adenocarcinoma patients: A proof-of-concept.
    Martinez-Useros J, Georgiev-Hristov T, Fernández-Aceñero MJ, Borrero-Palacios A, Indacochea A, Guerrero S, Li W, Cebrián A, Gómez Del Pulgar T, Puime-Otin A, Del Puerto-Nevado L, Rodríguez-Remírez M, Pérez N, Celdrán A, Gebauer F, Garcia-Foncillas J.
    PLoS One; 2017 May 13; 12(8):e0182044. PubMed ID: 28763470
    [Abstract] [Full Text] [Related]

  • 6. Linc00675 is a novel marker of short survival and recurrence in patients with pancreatic ductal adenocarcinoma.
    Li DD, Fu ZQ, Lin Q, Zhou Y, Zhou QB, Li ZH, Tan LP, Chen RF, Liu YM.
    World J Gastroenterol; 2015 Aug 21; 21(31):9348-57. PubMed ID: 26309360
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Meta-analysis of transcriptome data identifies a novel 5-gene pancreatic adenocarcinoma classifier.
    Bhasin MK, Ndebele K, Bucur O, Yee EU, Otu HH, Plati J, Bullock A, Gu X, Castan E, Zhang P, Najarian R, Muraru MS, Miksad R, Khosravi-Far R, Libermann TA.
    Oncotarget; 2016 Apr 26; 7(17):23263-81. PubMed ID: 26993610
    [Abstract] [Full Text] [Related]

  • 9. Prognostic Fifteen-Gene Signature for Early Stage Pancreatic Ductal Adenocarcinoma.
    Chen DT, Davis-Yadley AH, Huang PY, Husain K, Centeno BA, Permuth-Wey J, Pimiento JM, Malafa M.
    PLoS One; 2015 Apr 26; 10(8):e0133562. PubMed ID: 26247463
    [Abstract] [Full Text] [Related]

  • 10. Circulating Tumor Cells Expressing Markers of Tumor-Initiating Cells Predict Poor Survival and Cancer Recurrence in Patients with Pancreatic Ductal Adenocarcinoma.
    Poruk KE, Blackford AL, Weiss MJ, Cameron JL, He J, Goggins M, Rasheed ZA, Wolfgang CL, Wood LD.
    Clin Cancer Res; 2017 Jun 01; 23(11):2681-2690. PubMed ID: 27789528
    [Abstract] [Full Text] [Related]

  • 11. A gene expression signature of epithelial tubulogenesis and a role for ASPM in pancreatic tumor progression.
    Wang WY, Hsu CC, Wang TY, Li CR, Hou YC, Chu JM, Lee CT, Liu MS, Su JJ, Jian KY, Huang SS, Jiang SS, Shan YS, Lin PW, Shen YY, Lee MT, Chan TS, Chang CC, Chen CH, Chang IS, Lee YL, Chen LT, Tsai KK.
    Gastroenterology; 2013 Nov 01; 145(5):1110-20. PubMed ID: 23896173
    [Abstract] [Full Text] [Related]

  • 12. Prognostic and Functional Significance of MAP4K5 in Pancreatic Cancer.
    Wang OH, Azizian N, Guo M, Capello M, Deng D, Zang F, Fry J, Katz MH, Fleming JB, Lee JE, Wolff RA, Hanash S, Wang H, Maitra A.
    PLoS One; 2016 Nov 01; 11(3):e0152300. PubMed ID: 27023625
    [Abstract] [Full Text] [Related]

  • 13. Identification of candidate miRNA biomarkers for pancreatic ductal adenocarcinoma by weighted gene co-expression network analysis.
    Giulietti M, Occhipinti G, Principato G, Piva F.
    Cell Oncol (Dordr); 2017 Apr 01; 40(2):181-192. PubMed ID: 28205147
    [Abstract] [Full Text] [Related]

  • 14. CD44 Predicts Early Recurrence in Pancreatic Cancer Patients Undergoing Radical Surgery.
    Hsu CP, Lee LY, Hsu JT, Hsu YP, Wu YT, Wang SY, Yeh CN, Chen TC, Hwang TL.
    In Vivo; 2018 Apr 01; 32(6):1533-1540. PubMed ID: 30348713
    [Abstract] [Full Text] [Related]

  • 15. Identification of microRNA-21 as a biomarker for chemoresistance and clinical outcome following adjuvant therapy in resectable pancreatic cancer.
    Hwang JH, Voortman J, Giovannetti E, Steinberg SM, Leon LG, Kim YT, Funel N, Park JK, Kim MA, Kang GH, Kim SW, Del Chiaro M, Peters GJ, Giaccone G.
    PLoS One; 2010 May 14; 5(5):e10630. PubMed ID: 20498843
    [Abstract] [Full Text] [Related]

  • 16. FOXO3 is essential for CD44 expression in pancreatic cancer cells.
    Kumazoe M, Takai M, Bae J, Hiroi S, Huang Y, Takamatsu K, Won Y, Yamashita M, Hidaka S, Yamashita S, Yamada S, Murata M, Tsukamoto S, Tachibana H.
    Oncogene; 2017 May 11; 36(19):2643-2654. PubMed ID: 27893718
    [Abstract] [Full Text] [Related]

  • 17. Expression and Clinical Significance of Cancer Stem Cell Markers CD24, CD44, and CD133 in Pancreatic Ductal Adenocarcinoma and Chronic Pancreatitis.
    Durko L, Wlodarski W, Stasikowska-Kanicka O, Wagrowska-Danilewicz M, Danilewicz M, Hogendorf P, Strzelczyk J, Malecka-Panas E.
    Dis Markers; 2017 May 11; 2017():3276806. PubMed ID: 28659655
    [Abstract] [Full Text] [Related]

  • 18. Genetic variability of the ABCC2 gene and clinical outcomes in pancreatic cancer patients.
    Gentiluomo M, Puchalt García P, Galeotti AA, Talar-Wojnarowska R, Tjaden C, Tavano F, Strobel O, Kupcinskas J, Neoptolemos J, Hegyi P, Costello E, Pezzilli R, Sperti C, Lawlor RT, Capurso G, Szentesi A, Soucek P, Vodicka P, Lovecek M, Hackert T, Cavestro GM, Milanetto AC, Canzian F, Campa D.
    Carcinogenesis; 2019 Jun 10; 40(4):544-550. PubMed ID: 30629142
    [Abstract] [Full Text] [Related]

  • 19. Low RASSF6 expression in pancreatic ductal adenocarcinoma is associated with poor survival.
    Ye HL, Li DD, Lin Q, Zhou Y, Zhou QB, Zeng B, Fu ZQ, Gao WC, Liu YM, Chen RW, Li ZH, Chen RF.
    World J Gastroenterol; 2015 Jun 07; 21(21):6621-30. PubMed ID: 26074700
    [Abstract] [Full Text] [Related]

  • 20. A 15-Inflammation-Related Gene Signature Predicts the Prognosis of Patients With Pancreatic Ductal Adenocarcinoma.
    Sun X, Song H, Sun X, Liao C, Wang G, Xu Y, Li L, Han Y, Xu C, Wang W, Cai S, Liang H, Yu H.
    Cancer Invest; 2024 Mar 07; 42(3):226-242. PubMed ID: 38616304
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.